Sweden caps liraglutide prescribing to 10 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger in 2025
Page 8 of 10 of this archive, newest first.
A tested vial is evidence about a vial
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
What STEP 8 tells us about maintenance, and what it does not
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
Singapore caps dulaglutide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Why a result on one vial says less than the trade needs it to
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
SURMOUNT-OSA was built to answer the stopping question, and it did
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
Mexico declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
A design note on withdrawal trials, and why the run-in matters
The regain trajectories, arm by arm, with the estimands named.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
New Zealand caps exenatide prescribing to 16 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
The Journal does not treat a badge as evidence and states so wherever it reports one.
Portugal declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Australia caps exenatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The supply gap as a clinical event
The trials studied planned withdrawal. Almost nobody stops that way.
Portugal declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The United Arab Emirates caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Chain of custody, and where it begins
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
A tested vial is evidence about a vial
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
What a split-sample exercise can establish, and what it cannot
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Norway caps exenatide prescribing to 12 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.